| Name | Title | Contact Details |
|---|
PAVmed (NASDAQ: PAVM) is a highly-differentiated, multi-product medical device company employing a unique and proven business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This model enables us to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation.
Asian Medical is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clarity Medical Systems, Inc. is a medical device company that develops, manufactures and markets integrated optical systems and services to enhance the clinician`s ability to diagnose, manage, and treat eye disorders. These patented devices combine innovative 21st century optical, electronic and information technologies that change the very nature of eye healthcare. The Company`s initial product line has improved the standard of eye healthcare for pediatrics and is sold to leading Neonatal Intensive Care Units on a global basis. The Company`s first product line, the RetCam, is a major achievement in providing miniaturized, integrated, wide-field imaging for management of eye disorders in infants. The RetCam has revolutionized disease management for pediatric eye disorders and has been the enabling tool for several international clinical trials. Customers include: Stanford University, Bascom-Palmer Eye Institute, UCLA Jules Stein Eye Institute, Toronto Hospital for Sick Kids, Cleveland Clinic, USC Children`s Hospital, and Wills Eye Institute.
Warner Tech-Care Products is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MY01 is a state-of-the-art medical device geared towards aiding in the detection of Compartment Syndrome (CS); a limb-threatening muscle condition that occurs within 48 hours following trauma. Currently, ACS is diagnosed based on subjective and unreliable outcomes like pain (known as 6 P`s), which when present cannot confirm the diagnosis in time for effective intervention. This leads to increased complications (muscle necrosis/amputation) and costs the US healthcare system more than $2.25 B annually. MY01 is capitalizing on a proven correlation between sustained increase in Intramuscular pressures and ACS for objective, early diagnosis. MY01 operationalizes muscular pressure monitoring into a simple, accurate single-use device. MY01. The simple solution to a dangerous problem.